2024 - Advancing CAR T-Cell Therapies with Clinical Trial Customization

Bringing together best practices in genomics, flow cytometry, biomarkers and clinical trial operations
In the ever-evolving landscape of healthcare, cell and gene therapy (CGT) stands at the forefront of groundbreaking advancements. With the power to precisely manipulate cells and genes for therapeutic purposes, it offers immense promise in treating diseases at their root. A significant breakthrough in CGT has been the use of chimeric antigen receptor-engineered T cells (CAR T cells) for treating cancer. The industry faces many challenges such as a changing complex regulatory environment and technology for CAR T-cell-based therapeutics. Introducing new CAR T-cell therapies to the market requires extensive strategizing and planning for clinical trials as well as post-marketing follow-up.
CAR T-cell therapies are highly personalized, and therefore clinical trials need customized testing solutions. The pharma and biotech communities preparing for clinical development and ultimately market launch need to consider this in their clinical trial strategies, including patient selection and therapy delivery. One key consideration is engaging with contract research organizations (CROs) and lab service providers at an early stage to ensure that clinical trials can be designed based on customized needs.
Read more...
Register for this webinar today to learn more about customized solutions for successful CAR T-cell therapy clinical trials. 
Keywords: Drug Development, Precision Medicine, Clinical Research, CRO, Oncology, Therapeutics, Cell Therapy, Biomarkers, Genomics, Biotherapeutics, Therapeutic Areas, CAR T-Cell Therapy, Bioanalytical Testing, Cell and Gene Therapy, Cell & Gene Therapies